Analyst Price Targets — ABCL
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| August 11, 2026 1:30 pm | — | Truist Financial | $30.00 | $10.08 | TheFly | AbCellera price target raised to $30 from $12 at Truist |
| August 6, 2026 12:19 pm | — | Stifel Nicolaus | $9.00 | $6.12 | TheFly | AbCellera price target raised to $9 from $8 at Stifel |
| May 12, 2026 10:50 am | — | Stifel Nicolaus | $8.00 | $5.25 | TheFly | AbCellera price target raised to $8 from $7 at Stifel |
| May 5, 2026 10:34 am | — | Cantor Fitzgerald | $7.00 | $4.59 | TheFly | AbCellera initiated with an Overweight at Cantor Fitzgerald |
| November 5, 2024 1:14 pm | Gary Nachman | BMO Capital | $5.00 | $2.74 | StreetInsider | AbCellera Biologics (ABCL) PT Lowered to $5 at BMO Capital |
| August 23, 2024 11:57 am | Scott Schoenhaus | KeyBanc | $5.00 | $2.60 | StreetInsider | KeyBanc Reiterates Overweight Rating on AbCellera Biologics (ABCL) |
| May 8, 2024 2:46 am | Scott Schoenhaus | KeyBanc | $7.00 | $3.84 | StreetInsider | AbCellera Biologics (ABCL) PT Lowered to $7 at KeyBanc |
| January 6, 2023 9:07 am | — | Leerink Partners | $18.00 | $9.63 | Benzinga | SVB Leerink Maintains Outperform on AbCellera Biologics, Lowers Price Target to $18 |
| December 15, 2022 4:41 am | Andrea Tan | Goldman Sachs | $30.00 | $10.13 | TheFly | AbCellera initiated with a Buy at Goldman Sachs |
| November 16, 2022 7:11 am | — | Truist Financial | $29.00 | $14.49 | Benzinga | Truist Securities Initiates Coverage On AbCellera Biologics with Buy Rating, Announces Price Target of $29 |
Latest News for ABCL
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera to Present at the Cantor Global Healthcare Conference on September 9, 2026.
BlackRock Inc. purchased a new position in shares of AbCellera Biologics Inc. (NASDAQ: ABCL) during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 3,805,309 shares of the company's stock, valued at approximately $29,872,000. BlackRock Inc. owned 1.25% of AbCellera
AbCellera Biologics Inc. (NASDAQ:ABCL) stock is trading higher on Tuesday. Year-to-date, the stock has jumped over 250%.
Biotech, especially small-cap names, is experiencing renewed optimism as macro and policy headwinds subside, driving sector-wide rallies. Stabilization at the FDA and a resurgence in M&A and IPO activity are restoring capital flows and investor confidence in biotech equities.
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Announces Pricing of Oversubscribed $200 Million Public Offering of Common Shares and Pre-Funded Warrants.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for ABCL.
U.S. House Trading
No House trades found for ABCL.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.